Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu
Trial record 37 of 56 for:    insys

Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00100672
Recruitment Status : Completed
First Posted : January 5, 2005
Last Update Posted : July 4, 2011
Information provided by:
INSYS Therapeutics Inc

Brief Summary:

The primary purpose of this study is to identify a dose of Liposome Entrapped c-raf Antisense Oligonucleotide Easy-to-Use (LErafAON-ETU) which maximizes potential benefits of the compound to patients with advanced cancer, without compromising their safety. This study will also assess the processing of LErafAON-ETU by the body over time. Patients will receive an intravenous infusion of LErafAON-ETU each week. Multiple blood samples will be taken for pharmacokinetic analysis during the first treatment; two samples will be taken during both the second and third treatments. Patients will be eligible to continue treatment until the occurrence of unacceptable toxicity or disease progression.

In LErafAON-ETU, antisense oligonucleotides specific to c-raf, are associated with liposomes, which are microscopic membrane-like structures created from lipids (fats). Raf-1 is a protein which plays a critical role in many aspects of cellular activation and growth. Therefore, it is thought to be an important factor that may support tumor development. LErafAON-ETU potentially limits the ability of a cell to produce the Raf-1 protein.

Condition or disease Intervention/treatment Phase
Neoplasms Drug: LErafAON-ETU Phase 1

Detailed Description:
This Phase I, open-label, dose-escalation study is designed to determine the maximum tolerated dose of LErafAON-ETU in patients who have advanced cancer considered unresponsive to available, conventional modalities or treatments. LErafAON-ETU will be administered as an IV infusion once weekly for 3 consecutive weeks (a Treatment Cycle). A complete pharmacokinetic profile of raf-1 antisense oligonucleotide will be assessed in week 1 only; limited pharmacokinetic sampling will be done prior to and at the end of infusion in weeks 2 and 3 only. Tumor/disease evaluation will be performed upon completion of 6 infusions (2 Cycles). Dose escalation will not occur until the safety and tolerability at a given dose level has been confirmed for 1 Cycle.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of an Easy-to-Use Intravenous Formulation of Liposome Entrapped C-raf Antisense Oligonucleotide (LErafAON-ETU) Administered on a Weekly Schedule in Patients With Advanced Cancer
Study Start Date : December 2004
Actual Primary Completion Date : October 2009
Actual Study Completion Date : November 2010

Primary Outcome Measures :
  1. To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of LErafAON-ETU.

Secondary Outcome Measures :
  1. To determine the pharmacokinetics of raf antisense oligonucleotide after intravenous administration of LErafAON-ETU
  2. To determine any anti-tumor effects of LErafAON-ETU.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

To be included in this study, patients must meet the following criteria:

  • Be ≥18 years of age.
  • Have advanced (local and/or metastatic) histologically documented cancer not considered responsive to available conventional modalities or treatment (i.e., no life prolonging therapy or therapy with a greater potential for patient benefit is available).
  • Have an ECOG Performance status of 0-1.
  • Have a life expectancy of >12 weeks.
  • Have recovered from acute toxicities of prior treatment: *No treatment with radiotherapy or with cytotoxic or biologic agents within 3 weeks prior to study entry. At least 2 weeks must have elapsed since any prior surgery or granulocyte-stimulating growth factor therapy. Chronic treatment with non-investigational gonadotropin-releasing hormone agonists or other hormonal or supportive care is permitted. Concurrent bisphosphonate treatment is permitted if initiated ≥90 days prior to study entry. *Chronic Grade 1 toxicities due to prior treatment or other causes are permitted.
  • Be in adequate condition as evidenced by the following clinical laboratory values:

    • Absolute neutrophil count (ANC) ≥1,500/mm³,
    • Hemoglobin ≥9.0 g/dL,
    • Platelets ≥125,000/mm³,
    • PT, aPTT, creatinine, calcium, and total bilirubin ≤the institutional upper limit of normal (ULN),
    • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 x ULN,
    • Alkaline phosphatase ≤2.5 x ULN
  • Patients (male and female) must be willing to practice an effective method of birth control during the study.
  • Patient must understand the investigational nature of this study and sign an Institutional Review Board (IRB) approved informed consent form prior to the performance of any study specific procedure.

Exclusion Criteria:

Patients are excluded from this study for the following:

  • Active uncontrolled bleeding or bleeding diathesis (e.g., active peptic ulcer disease).
  • Any active infection requiring parenteral or oral antibiotic treatment.
  • Known infection with human immunodeficiency virus or hepatitis virus.
  • Active heart disease including myocardial infarction within the previous 6 months, symptomatic coronary artery disease, arrhythmias currently requiring medication, or congestive heart failure.
  • Known or suspected active central nervous system metastasis (patients stable 8 weeks after completion of treatment for central nervous system metastasis are eligible).
  • Requiring immediate palliative treatment of any kind, including surgery and/or radiotherapy
  • Concurrent anti-tumor therapy (except for chronic hormonal anti-tumor therapy).
  • Treatment with any investigational drug within the 30-day period prior to enrollment in the study.
  • Known hypersensitivity to any of the components of LErafAON-ETU.
  • Prior treatment with LErafAON (previous sonicated formulation).
  • Female patients who are pregnant or breast-feeding.
  • Unwilling or unable to follow protocol requirements.
  • Any consideration which in the Investigator's opinion deems the patient an unsuitable candidate to receive study drug.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00100672

Layout table for location information
United States, Arizona
premiere Oncology-Arizona
Scottsdale, Arizona, United States, 85260
United States, California
Premiere Oncology-Santa Monica
Santa Monica, California, United States, 90404
Sponsors and Collaborators
INSYS Therapeutics Inc

Layout table for additonal information Identifier: NCT00100672    
Other Study ID Numbers: LErafAON-ETU-104-R02
First Posted: January 5, 2005    Key Record Dates
Last Update Posted: July 4, 2011
Last Verified: June 2011
Keywords provided by INSYS Therapeutics Inc:
Signal transduction
Advanced neoplasm
Advanced cancer
Refractory cancer
Metastatic cancer
Additional relevant MeSH terms:
Layout table for MeSH terms